News
Article
Author(s):
Genentech broke ground on a $700 million manufacturing facility in Holly Springs, North Carolina its first on the U.S. East Coast supporting next-generation obesity treatments and metabolic medicines as part of Roche’s broader $50 billion U.S. investment in innovation, job creation, and advanced biomanufacturing.
The new $700 million manufacturing facility is part of Roche’s $50 billion investment in U.S. manufacturing and research & development.
Stock.adobe.com
Genentech, a member of the Roche group, announced it has broken ground for its newest U.S. manufacturing site in Holly Springs, North Carolina. The company’s first manufacturing site on the East Coast, the facility is designed to support the production of Genentech’s future pipeline including, metabolic medicines and next-generation obesity treatments.
Roche Group CEO Thomas Schinecker spoke on the importance of the new manufacturing site, saying, “I am proud to break ground on our new state-of-the-art manufacturing facility in North Carolina, which will support the production of our next-generation obesity treatments. This $700 million project is an integral part of our broader $50 billion commitment to further expand our already significant presence in the United States, building on our 120-year legacy of driving innovation and creating jobs across America. I am excited about the impact this facility will have on delivering life-changing medicines to patients in the US and around the world.”1
The new manufacturing site in Holly Springs estimated to be upwards of $700 million, is part of Roche’s $50 billion investment in U.S.-based manufacturing, along with research and development. It’s estimated that this facility will generate more than 1,900 new jobs, providing benefits to both the local community, and the pharmaceutical industry.
Roche selected Holly Springs, due to the following:
Roche’s $50 billion investment will see this new manufacturing facility, designed for high-volume, efficient, and sustainable production, complement its established portfolio of manufacturing site around the world. Genentech anticipates the facility to be fully constructed and operational by 2029, and will integrate modern biomanufacturing technology along with advanced automation and digital capabilities. Roche and Genentech additionally planned to include space for future expansions within the 400,000 m² lot.
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
